Bacteriophages for treatment of tuberculosis
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsGraham F. Hatfull, Carlos Andrés Guerrero, Rebekah Marie Dedrick
Life of this patent
Estimating the term…
Abstract
Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.
Claims20
A pharmaceutical composition comprising a combination of five or more phages selected from the group consisting of D29, AdephagiaΔ41Δ43, ZoeJΔ45, FionnbharthΔ47, FionnbharthΔ45Δ47, CG-REM-1, CG-REM-2, Fred313cpm-1, Fred313cpm-1Δ33, MuddyHRMN0052-1, Muddy_HRMN0157-2, and DS6A
- and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, propylene glycol, polyethylene glycol, alcohol, and any combination thereof.
Dependencies are inferred from the claim text.